Continuum Advisory, LLC Recursion Pharmaceuticals, Inc. Transaction History
Continuum Advisory, LLC
- $660 Million
- Q1 2024
A detailed history of Continuum Advisory, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Continuum Advisory, LLC holds 300 shares of RXRX stock, worth $2,196. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300Holding current value
$2,196% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RXRX
# of Institutions
260Shares Held
192MCall Options Held
787KPut Options Held
1.52M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl24.6MShares$180 Million1.75% of portfolio
-
Baillie Gifford & CO24.1MShares$176 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA16MShares$117 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.3MShares$90.2 Million0.0% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V710.4MShares$76.2 Million100.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.32B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...